Delcath Systems Inc

DCTHNASDAQUSD
12.81 USD
0.04 (0.31%)AT CLOSE (11:59 AM EDT)
12.81
0.00 (0.01%)
POST MARKET (AS OF 04:24 PM EDT)
Post Market
AS OF 04:24 PM EDT
12.81
0.00 (0.01%)
🔴Market: CLOSED

DCTH is currently priced at $12.83. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, DCTH trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jul 17, 2026.

Open?$12.52
High?$13.05
Low?$12.32
Prev. Close?$12.85
Volume?369.3K
Avg. Volume?522.9K
VWAP?$12.87
Rel. Volume?0.71x
Bid / Ask
Bid?$10.77 × 100
Ask?$15.14 × 100
Spread?$4.37
Midpoint?$12.96
Valuation & Ratios
Market Cap?443.6M
Shares Out?34.5M
Float?28.8M
Float %?83.6%
P/E Ratio?790.74
P/B Ratio?3.94
EPS?$0.02
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Employees
156
Market Cap
443.6M
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed
2000-10-19
Address
566 QUEENSBURY AVENUE
QUEENSBURY, NY 12804
Phone: (518) 743-8892
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
100
Momentum?
62
Short Sent.?
45
Piotroski F-Score?1/9Weak
Altman Z-Score?17.74Safe
Confidence?51%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?9.94%Elevated
Short Interest?2.9M
Days to Cover?4.9
Free Float28.8M
Avg Daily Volume591.1K
Settlement Date2026-06-30
Financial Health
Current Ratio?11.24Strong
Quick Ratio?10.33Strong
Cash Ratio?3.86Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
Peers
100
S&P
3
790.7PRICEY
P/B?
Peers
100
S&P
45
3.94FAIR
P/S?
Peers
100
S&P
30
4.90FAIR
P/FCF?
Peers
100
S&P
45
23.1FAIR
EV/EBITDA?
S&P
97
-304.3CHEAP
EV/Sales?
Peers
100
S&P
41
4.45FAIR
Returns & Efficiency
ROE?
Peers
50
S&P
16
0.5%WEAK
ROA?
Peers
50
S&P
9
0.4%WEAK
Cash Flow & Enterprise
FCF?$19.2M
Enterprise Value?$402.3M
Fundamentals ratios updated end of day